Main Industry
Biotechnology
Main Product/Service
The company’s lead product, OBI‑858, is a novel 760 kDa botulinum toxin derived from Clostridium botulinum type A. OBI‑858 has successfully completed a Phase I clinical trial, demonstrating excellent safety, tolerability, and preliminary efficacy in reduc
The content above was translated by Ai
Founded Year
2020
Unified Business No.
82943056
Status
Active
Number of Employees
0
Total Paid-in
Capital
1,072,617,500 (NT$)
Location of Company
Taiwan
, Hsinchu County
Company names, registration status, legal representatives, founding years, paid-in capital, registered addresses, and other details are sourced from business registration records maintained by Taiwan’s Administration of Commerce, Ministry of Economic Affairs. Exit status includes Emerging Stock Board listings, M&A, and IPOs. Information on overseas expansion is self-reported by startups.
Note 1: FINDIT compiles company information from public and other sources for reference and does not serve as a point of contact for the companies listed.
Note 2: Some company profiles and product/service descriptions are translated using AI and provided for reference only. In case of discrepancies or ambiguity, the original text prevails.
Exclusive content for members
Members-only content. Please log in to access.
About the Company
OBIGEN Pharma, also known as Ding‑Jin Biotech, is the first Taiwan-based company dedicated to the research, development, and manufacturing of its own botulinum toxin products. The company operates under stringent safety and quality standards, maintaining PIC/s‑GMP–certified raw‑material and sterile production facilities.
The content above was translated by Ai
